PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.

Quotes for PharmaLundensis AB

Right Now

+/-
0
%
0,00%
Latest
0.42
High
0.42
Low
0.42
Volume
6 934
Turnover (SEK)
2 912
Market Value (MSEK)
15,2
Time (Latest trade)

Board

CEO

  • Staffan Skogvall

Chairperson of the Board

  • Arne Skogvall

Board

  • Bo Wennergren
  • Björn Sivik
  • Staffan Skogvall
  • Stefan Ahlfors

Largest Owners

Name Capital % Votes % Date
Staffan Skogvall 50,15 50,15 2023-11-07
Vict Th Engwalls Stiftelse 1,79 1,79 2023-09-27
Avanza Pension 1,63 1,63 2023-09-27
Henrik Skog 1,14 1,14 2023-09-27
Arne Arvidsson 1,10 1,10 2023-09-27
Nordnet Pensionsförsäkring 0,94 0,94 2023-09-27
Staffan Engelbert Bodén 0,65 0,65 2023-09-27
Arne Skogvall 0,61 0,61 2023-09-27
Tommy Johansson 0,55 0,55 2023-09-27
Torsten Ingemar Jonsson 0,55 0,55 2023-09-27
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2024-02-15 Bokslutskommuniké 2023

Annual reports, prospectus etc.